↓ Skip to main content

Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis

Overview of attention for article published in BMC Nephrology, January 2021
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (56th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (63rd percentile)

Mentioned by

policy
1 policy source

Citations

dimensions_citation
15 Dimensions

Readers on

mendeley
38 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis
Published in
BMC Nephrology, January 2021
DOI 10.1186/s12882-020-02190-0
Pubmed ID
Authors

Anja Gäckler, Ulf Schönermarck, Vladimir Dobronravov, Gaetano La Manna, Andrew Denker, Peng Liu, Maria Vinogradova, Sung-Soo Yoon, Manuel Praga

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 38 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 38 100%

Demographic breakdown

Readers by professional status Count As %
Other 4 11%
Student > Postgraduate 3 8%
Student > Bachelor 2 5%
Student > Master 2 5%
Student > Ph. D. Student 1 3%
Other 2 5%
Unknown 24 63%
Readers by discipline Count As %
Medicine and Dentistry 5 13%
Nursing and Health Professions 4 11%
Biochemistry, Genetics and Molecular Biology 1 3%
Immunology and Microbiology 1 3%
Pharmacology, Toxicology and Pharmaceutical Science 1 3%
Other 4 11%
Unknown 22 58%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 June 2023.
All research outputs
#7,972,127
of 23,986,470 outputs
Outputs from BMC Nephrology
#914
of 2,590 outputs
Outputs of similar age
#192,828
of 509,303 outputs
Outputs of similar age from BMC Nephrology
#24
of 65 outputs
Altmetric has tracked 23,986,470 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,590 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.1. This one has gotten more attention than average, scoring higher than 61% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 509,303 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 56% of its contemporaries.
We're also able to compare this research output to 65 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 63% of its contemporaries.